版塊導(dǎo)航: 正在加載中...

應(yīng)《網(wǎng)絡(luò)安全法》要求，自2017年10月1日起，未進(jìn)行實(shí)名認(rèn)證將不得使用互聯(lián)網(wǎng)跟帖服務(wù)。為保障您的帳號(hào)能夠正常使用，請(qǐng)盡快對(duì)帳號(hào)進(jìn)行手機(jī)號(hào)驗(yàn)證，感謝您的理解與支持！

24小時(shí)熱門版塊排行榜

北京石油化工學(xué)院2026年研究生招生接收調(diào)劑公告

返回列表

本帖產(chǎn)生 1 個(gè) 翻譯EPI ，點(diǎn)擊這里進(jìn)行查看

霜葉

金蟲 (小有名氣)

應(yīng)助: 0 (幼兒園)
金幣: 1205.8
散金: 20
帖子: 262
在線: 39.9小時(shí)
蟲號(hào): 284891
注冊(cè): 2006-10-14
性別: MM
專業(yè): 臨床藥理

[求助] 求助翻譯一段摘要，非常感謝

Summary This study set out to evaluate, in patients with metastatic colorectal carcinoma, the efficacy and toxicity of S-1, which contains
tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate, based on a biochemical modulation of 5-fluorouracil (5-FU) targeted
at inhibition of dihydropyrimidine dehydrogenase (DPD). Sixty-three patients with measurable metastatic colorectal carcinoma were enrolled
into the study. None of the patients had received prior chemotherapy except for adjuvant setting. S-1 was administered orally twice daily at a
(R)C (R)C
standard dose of 80mg m day for 28 days followed by a 14-day rest. This agent is continued until disease progression, unaccepted
toxicity, or patient refusal. Twenty-two (35%) of the 62 eligible patients achieved PR with a 95% confidence interval of 25(R)C48. Five of the 10
patients with a history of adjuvant chemotherapy achieved partial remission. The median survival time was 12 months. Major adverse
reactions included myelosuppressive and gastrointestinal toxicities, though their incidence of grade 3 or 4 being 13% in neutropenia and less
than 10% in the others. None of the 53 patients treated as outpatients required hospitalization due to adverse reactions: These results
suggest that S-1 achieves similar responses to those of infusional 5-FU plus leucovorin and shows the potential of another biochemical
modulation with easily manageable toxicity.

回復(fù)此樓

» 猜你喜歡

一志愿大連理工大學(xué)材料求調(diào)劑已經(jīng)有5人回復(fù)
材料與化工調(diào)劑一志愿大連海事085600，349 已經(jīng)有6人回復(fù)
一志愿中海洋320化學(xué)工程與技術(shù)學(xué)碩求調(diào)劑已經(jīng)有4人回復(fù)
材料科學(xué)與工程調(diào)劑已經(jīng)有11人回復(fù)
311求調(diào)劑一志愿合肥工業(yè)大學(xué) 已經(jīng)有4人回復(fù)
一志愿食品科學(xué)與工程083200求調(diào)劑已經(jīng)有4人回復(fù)
材料科學(xué)與工程求調(diào)劑已經(jīng)有10人回復(fù)
一志愿北化085600材料專碩275|有文章專利｜求調(diào)劑已經(jīng)有11人回復(fù)
一志愿南京航空航天大學(xué) ，080500材料科學(xué)與工程學(xué)碩已經(jīng)有4人回復(fù)
085600材料與化工調(diào)劑已經(jīng)有15人回復(fù)

1樓 2013-02-26 15:48:32

已閱回復(fù)此樓關(guān)注TA 給TA發(fā)消息送TA紅花 TA的回帖

hillatmsu

木蟲 (小有名氣)

翻譯EPI: 15
應(yīng)助: 46 (小學(xué)生)
金幣: 5577.5
紅花: 2
帖子: 200
在線: 117.3小時(shí)
蟲號(hào): 2236855
注冊(cè): 2013-01-12
性別: GG
專業(yè): 有機(jī)化工

【答案】應(yīng)助回帖

★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
霜葉: 金幣+40, 翻譯EPI+1, ★★★★★最佳答案, 非常感謝啦 2013-02-27 10:28:13

試試看

摘要：本研究旨在評(píng)測(cè)含有替加氟，5-氯-2,4-二羥基吡啶（CDHP）和氧嗪酸鉀的S-1對(duì)于轉(zhuǎn)移性結(jié)腸直腸癌病人的療效和毒副作用。這項(xiàng)評(píng)測(cè)是以5 - 氟尿嘧啶（5-FU）有針對(duì)性的抑制二氫嘧啶脫氫酶（DPD）這種生化調(diào)解作用為基礎(chǔ)的。63位檢測(cè)有轉(zhuǎn)移性大腸癌的病人參加了這項(xiàng)研究。除了輔助治療外，這些病人之前沒有接受過任何化療。病人們首先連續(xù)28天每日兩次按照（R）C（R）C標(biāo)準(zhǔn)劑量口服80mg S-1，接下來14天進(jìn)行休息。這項(xiàng)療程持續(xù)進(jìn)行到疾病擴(kuò)展、出現(xiàn)不可接受的毒性作用或者病人拒絕為止。62位符合條件的病人中有22個(gè)（35%）達(dá)到了95%的25（R）C48置信區(qū)間的PR比。10位有過輔助化療歷史的病人中有5位實(shí)現(xiàn)了部分緩解。中位生存期為12個(gè)月。主要不良反應(yīng)包括骨髓抑制和胃腸道毒性，但其3或4級(jí)發(fā)病率為13%的中性粒細(xì)胞減少，和10%的胃腸道毒性。作為門診病人的53位患者沒有因?yàn)椴涣挤磻?yīng)而需要住院的。這些結(jié)果表明S-1能夠?qū)崿F(xiàn)與注射5-FU加甲酰四氫葉酸類似的反應(yīng)，并且顯示了這是一種毒性易控的生化調(diào)解方法。

贊一下

回復(fù)此樓

If I can help, I would

2樓2013-02-26 19:09:55